2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Omid Hamid, MD, and Grace Cherry, NP, share the importance of multidisciplinary care for patients with melanoma, how to best manage immunotherapy-related adverse events, and tips for developing trusting relationships with patients so that they feel comfortable reporting toxicities.
Welcome to a very special edition of OncLive On Air! I’m your host today, Gina Columbus.
OncLive On Air is a podcast from OncLive, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
But today, we collaborated with one of our sister brands, Oncology Nursing News (ONN), which delivers news and clinical insights for oncology nursing professionals. We teamed up with ONN Senior Editor Brielle Benyon, and sat down with Omid Hamid, MD, and Grace Cherry, NP. Hamid is chief of research, immune-oncology and co-director of the cutaneous malignancy program at the Angeles Clinic and Research Institute, and Cherry is of UCLA’s Melanoma Program.
In our exclusive interview, Dr. Hamid and Cherry shared the importance of multidisciplinary care for patients with melanoma, how to best manage immunotherapy-related adverse events, and tips for developing trusting relationships with patients so that they feel comfortable reporting toxicities. The key, they both explained, is to establish an open line of patient and provider communication to ensure that toxicities are reported—and handled—in a timely manner.
Related Content: